Terms: = Leukemia AND ELN, ENSG00000049540, 2006, WS, WBS, SVAS, FLJ43523, FLJ38671 AND Diagnosis
399 results:
1. Allogeneic haematopoietic cell transplantation for chronic myeloid leukaemia in Switzerland in the face of rapid development of effective drugs.
Heim D; Baldomero H; Medinger M; Masouridi-Levrat S; Schanz U; Nair G; Güngör T; Halter J; Passweg JR; Chalandon Y;
Swiss Med Wkly; 2024 May; 154():3754. PubMed ID: 38749067
[TBL] [Abstract] [Full Text] [Related]
2. [Treatment status of tyrosine kinase inhibitor for newly-diagnosed chronic myeloid leukemia: a domestic multi-centre retrospective real-world study].
Zhang XS; Liu BC; Du X; Zhang YL; Xu N; Liu XL; Li WM; Lin H; Liang R; Chen CY; Huang J; Yang YF; Zhu HL; Pan L; Wang XD; Li GH; Liu ZG; Zhang YQ; Liu ZF; Hu JD; Liu CS; Li F; Yang W; Meng L; Han YQ; Lin LE; Zhao ZY; Tu CQ; Zheng CF; Bai YL; Zhou ZP; Chen SN; Qiu HY; Yang LJ; Sun XL; Sun H; Zhou L; Liu ZL; Wang DY; Guo JX; Pang LP; Zeng QS; Suo XH; Zhang WH; Zheng YJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):215-224. PubMed ID: 38716592
[No Abstract] [Full Text] [Related]
3. [Update on the diagnosis and Stratification of Patients with Acute Myeloid leukemia: An Urgent National Need].
Jerez J; Briones JL; Buscaglia F; Torres C; Hidalgo S; Guerra MC; Goldschmidt V; Gazitúa R
Rev Med Chil; 2023 May; 151(5):628-638. PubMed ID: 38687545
[TBL] [Abstract] [Full Text] [Related]
4. Evaluating population-level outcomes in Chronic Lymphocytic leukemia in the era of novel therapies using the SEER registry.
Muthiah C; Narra R; Atallah E; Juan W; Szabo A; Guru Murthy GS
Leuk Res; 2024 May; 140():107496. PubMed ID: 38547577
[TBL] [Abstract] [Full Text] [Related]
5. Comparison of clinical outcomes of several risk stratification tools in newly diagnosed AML patients: A real-world evidence in our current therapeutic era.
Iat A; Loschi M; Benachour S; Calleja A; Chiche E; Sudaka I; Aquaronne D; Ferrero C; Fenwarth L; Marceau A; Fournier E; Dadone-Montaudie B; Cluzeau T
Cancer Med; 2024 Mar; 13(6):e7103. PubMed ID: 38506267
[TBL] [Abstract] [Full Text] [Related]
6. Late endocrine diseases in survivors of adolescent and young adult cancer in California: a population-based study.
Abrahão R; Brunson A; Ruddy KJ; Li Q; Li J; Ryder MM; Chubak J; Nichols HB; Sauder CAM; Gray MF; Hahn EE; Wun T; Keegan THM
Br J Cancer; 2024 Apr; 130(7):1166-1175. PubMed ID: 38332179
[TBL] [Abstract] [Full Text] [Related]
7. Management of ALL in adults: 2024 eln recommendations from a European expert panel.
Gökbuget N; Boissel N; Chiaretti S; Dombret H; Doubek M; Fielding A; Foà R; Giebel S; Hoelzer D; Hunault M; Marks DI; Martinelli G; Ottmann O; Rijneveld A; Rousselot P; Ribera J; Bassan R
Blood; 2024 May; 143(19):1903-1930. PubMed ID: 38306595
[TBL] [Abstract] [Full Text] [Related]
8. diagnosis, prognostic factors, and assessment of ALL in adults: 2024 eln recommendations from a European expert panel.
Gökbuget N; Boissel N; Chiaretti S; Dombret H; Doubek M; Fielding A; Foà R; Giebel S; Hoelzer D; Hunault M; Marks DI; Martinelli G; Ottmann O; Rijneveld A; Rousselot P; Ribera J; Bassan R
Blood; 2024 May; 143(19):1891-1902. PubMed ID: 38295337
[TBL] [Abstract] [Full Text] [Related]
9. Late venous thromboembolism in survivors of adolescent and young adult cancer: A population-based study in California.
Abrahão R; Brunson A; Chubak J; Wernli KJ; Nichols HB; Chao C; Ruddy KJ; Hahn EE; Li Q; Malogolowkin MH; Sauder CAM; Kushi LH; Wun T; Keegan THM
Thromb Res; 2024 Mar; 235():1-7. PubMed ID: 38244373
[TBL] [Abstract] [Full Text] [Related]
10. Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.
Nabergoj M; Eikema DJ; Koster L; Platzbecker U; Sockel K; Finke J; Kröger N; Forcade E; Nagler A; Eder M; Tischer J; Broers AEC; Kuball J; Wilson KMO; Hunault-Berger M; Collin M; Russo D; Corral LL; Helbig G; Mussetti A; Scheid C; Gurnari C; Raj K; Drozd-Sokolowska J; Yakoub-Agha I; Robin M; McLornan DP
Bone Marrow Transplant; 2024 Mar; 59(3):395-402. PubMed ID: 38195984
[TBL] [Abstract] [Full Text] [Related]
11. Mutations highly specific for secondary AML are associated with poor outcomes in eln favorable risk NPM1-mutated AML.
Chan O; Al Ali N; Tashkandi H; Ellis A; Ball S; Grenet J; Hana C; Deutsch Y; Zhang L; Hussaini M; Song J; Yun S; Talati C; Kuykendall A; Padron E; Walker A; Roboz G; Desai P; Sallman D; Sweet K; Komrokji R; Lancet J
Blood Adv; 2024 Mar; 8(5):1075-1083. PubMed ID: 38170740
[TBL] [Abstract] [Full Text] [Related]
12. Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia.
Cui J; Chen X; Li C; Yan Q; Yuan G
Hematology; 2024 Dec; 29(1):2293512. PubMed ID: 38095287
[TBL] [Abstract] [Full Text] [Related]
13. Metabolomic profile of acute myeloid leukaemia parallels of prognosis and response to therapy.
Bolkun L; Pienkowski T; Sieminska J; Godzien J; Pietrowska K; Kłoczko J; Wierzbowska A; Moniuszko M; Ratajczak M; Kretowski A; Ciborowski M
Sci Rep; 2023 Dec; 13(1):21809. PubMed ID: 38071228
[TBL] [Abstract] [Full Text] [Related]
14. Prognostic significance of the frequencies of bone marrow lymphocyte subsets in adult acute myeloid leukemia at diagnosis.
Sun K; Wang J; Wang YZ; Shi ZY; Chang Y; Yuan XY; Liu YR; Jiang H; Jiang Q; Huang XJ; Qin YZ
Int J Lab Hematol; 2024 Apr; 46(2):294-302. PubMed ID: 38069563
[TBL] [Abstract] [Full Text] [Related]
15. Understanding differential technologies for detection of MRD and how to incorporate into clinical practice.
Cloos J; Ngai LL; Heuser M
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):682-690. PubMed ID: 38066915
[TBL] [Abstract] [Full Text] [Related]
16. Clinical characteristics and treatment outcomes of Asian patients with T-cell large granular lymphocytic leukemia: a single-center analysis of 67 cases.
Park T; Byun JM; Shin DY; Koh Y; Hong J; Yoon SS; Chang YH; Kim I
Ann Hematol; 2024 Apr; 103(4):1235-1240. PubMed ID: 38062223
[TBL] [Abstract] [Full Text] [Related]
17. [To compare the efficacy and incidence of severe hematological adverse events of flumatinib and imatinib in patients newly diagnosed with chronic phase chronic myeloid leukemia].
Zhang XS; Liu BC; Du X; Zhang YL; Xu N; Liu XL; Li WM; Lin H; Liang R; Chen CY; Huang J; Yang YF; Zhu HL; Pan L; Wang XD; Li GH; Liu ZG; Zhang YQ; Liu ZF; Hu JD; Liu CS; Li F; Yang W; Meng L; Han YQ; Lin LE; Zhao ZY; Tu CQ; Zheng CF; Bai YL; Zhou ZP; Chen SN; Qiu HY; Yang LJ; Sun XL; Sun H; Zhou L; Liu ZL; Wang DY; Guo JX; Pang LP; Zeng QS; Suo XH; Zhang WH; Zheng YJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2023 Sep; 44(9):728-736. PubMed ID: 38049316
[No Abstract] [Full Text] [Related]
18. Test Then Erase? Current Status and Future Opportunities for Measurable Residual Disease Testing in Acute Myeloid leukemia.
Blackmon AL; Hourigan CS
Acta Haematol; 2024; 147(2):133-146. PubMed ID: 38035547
[TBL] [Abstract] [Full Text] [Related]
19. Expression and gene regulatory network of S100A16 protein in cervical cancer cells based on data mining.
Zhang H; Yang Y; Xing W; Li Y; Zhang S
BMC Cancer; 2023 Nov; 23(1):1124. PubMed ID: 37978469
[TBL] [Abstract] [Full Text] [Related]
20. Criteria for diagnosis and Molecular Monitoring of NPM1-Mutated AML.
Falini B; Dillon R
Blood Cancer Discov; 2024 Jan; 5(1):8-20. PubMed ID: 37917833
[TBL] [Abstract] [Full Text] [Related]
[Next]
